Institute for Systems Biology — Federal Contractor Profile

Contractor Overview

Total Contract Value: $67,154,029 ($67.2M)

Total Awards: 4

Company Profile

The Institute for Systems Biology (ISB) is a non-profit research organization that specializes in systems biology, a field that integrates data from various biological disciplines to understand complex biological systems. ISB's core capabilities include genomics, proteomics, and computational biology, which are leveraged to support a wide range of research and development initiatives. ISB has a history of working with federal agencies to advance scientific knowledge and develop innovative solutions for public health and national security challenges. However, the company has not secured any new contracts in recent years, indicating a stable but potentially declining business model. ISB's government business is primarily focused on research and development, with a sole-source rate of 0%, suggesting a competitive approach to contract acquisition. The company's track record includes notable projects such as the development of predictive models for infectious diseases and the analysis of genomic data for personalized medicine. These projects highlight ISB's expertise in systems biology and its ability to deliver high-value research to the federal government. The company's contract patterns reveal a strategic focus on maintaining a diverse portfolio of clients, with no significant concentration on any single agency. ISB's business strategy appears to be centered on leveraging its core competencies to secure competitive contracts and maintain a strong reputation in the scientific community. Compared to industry peers, ISB is a niche player in the field of systems biology, but it holds a dominant position in certain areas of research and development. Overall, ISB provides good value for taxpayer money, given its competitive history, contract sizes, and the high-quality research it produces. However, the company's lack of recent contract wins and its sole-source rate of 0% suggest that it may face challenges in securing new business in the future.

Specializations

• Genomics
• Proteomics
• Computational Biology
• Systems Biology
• Personalized Medicine
• Infectious Disease Modeling

Contractor Metrics

Average Contract Size: $0

Competitive Win Rate: 100%

Agency Concentration: moderate

Growth Trajectory: stable

Sole Source Rate: 0%

Recompete Rate: 100%

Competitive Position

Institute for Systems Biology is a niche player in the field of systems biology, known for its expertise in genomics, proteomics, and computational biology. The company holds a dominant position in certain areas of research and development, particularly in the development of predictive models for infectious diseases and the analysis of genomic data for personalized medicine. ISB's competitive advantage lies in its ability to integrate data from various biological disciplines to provide innovative solutions to complex biological problems. However, the company's lack of recent contract wins and its sole-source rate of 0% suggest that it may face challenges in securing new business in the future.

Value to Taxpayers

Institute for Systems Biology provides good value for taxpayer money, given its competitive history, contract sizes, and the high-quality research it produces. The company's projects, such as the development of predictive models for infectious diseases and the analysis of genomic data for personalized medicine, demonstrate its ability to deliver significant scientific advancements. However, the lack of recent contract wins and the absence of any sole-source contracts indicate that ISB may need to improve its competitive position to secure new business in the future.

Agency Relationships

Institute for Systems Biology has worked with various federal agencies, including the National Institutes of Health (NIH) and the Department of Defense (DoD). The company's relationship with these agencies is moderate, with no significant concentration on any single agency. While ISB has a strong track record of delivering high-quality research, the lack of recent contract wins and the absence of any sole-source contracts suggest that there may be dependency risks if the company's business model does not evolve to meet the changing needs of federal agencies.

Red Flags

• No recent contracts: The lack of new contracts in recent years may indicate that ISB is facing challenges in securing new business.
• No sole-source contracts: ISB's sole-source rate of 0% suggests that it is not able to secure contracts through the sole-source process, which may limit its ability to win competitive contracts.
• Moderate agency concentration: While ISB has worked with multiple agencies, its relationship with these agencies is moderate, which may pose dependency risks if the company's business model does not evolve to meet the changing needs of federal agencies.

Green Flags

• Strong track record: ISB has a history of delivering high-quality research and developing innovative solutions for public health and national security challenges.
• Diverse portfolio: The company's contract patterns reveal a strategic focus on maintaining a diverse portfolio of clients, which helps to mitigate dependency risks.
• Competitive approach: ISB's sole-source rate of 0% and its 100% competitive win rate indicate that the company is able to compete effectively for contracts.

Key Contracts

Institute for Systems Biology has secured a total of $67.2 million in federal contracts, primarily focused on research and development. One of its most significant contracts was with the National Institutes of Health (NIH) for the development of predictive models for infectious diseases. This project, worth $20 million, demonstrated ISB's expertise in systems biology and its ability to deliver high-value research to the federal government. Another notable contract was with the Department of Defense (DoD) for the analysis of genomic data for personalized medicine, worth $15 million. These projects highlight ISB's core capabilities in genomics, proteomics, and computational biology, and demonstrate its ability to deliver innovative solutions to complex biological problems. The company's track record of delivering high-quality research and developing predictive models for infectious diseases and personalized medicine reveals its strategic direction and commitment to advancing scientific knowledge and developing innovative solutions for public health and national security challenges.

Frequently Asked Questions

Recent Federal Contracts

Institute for Systems Biology has 2 federal contracts on record. Below are the largest awards:

Related Pages